ApiJect is a technology and innovation company that operates in the pharmaceutical industry, specifically in the area of drug delivery systems. The company's primary focus is on improving the fill-finish process of injectable medicines, a critical step in the production of pharmaceuticals where the drug is filled into its final container. ApiJect's technology combines Blow-Fill-Seal (BFS) aseptic drug packaging with connectable components to create high-quality, prefilled drug delivery systems. BFS is a method used to manufacture sterile, liquid pharmaceutical products that are packaged in a sealed container.

ApiJect's clients are pharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs) around the world. The company assists these clients in creating scalable, cost-efficient drug delivery systems and supports them in manufacturing these devices at their own facilities or a trusted contract manufacturer.

The company's business model is based on licensing its technology to these pharmaceutical companies and CDMOs. This includes drug-specific BFS mold and device design licensing, device design and development, prototype development, and BFS production support.

ApiJect has been recognized for its innovative approach, with its Prefilled Single-Dose Injector being a finalist in the prestigious CPHI Pharma Awards 2023 in the Drug Delivery & Device category. The company's engineers have also made advances in temperature management methods that could potentially enable the fill-finish of many temperature-sensitive biologics and vaccines.

Keywords: Drug Delivery Systems, Pharmaceutical Industry, Fill-Finish Process, Blow-Fill-Seal (BFS), Prefilled Single-Dose Injector, Licensing, Contract Development and Manufacturing Organizations (CDMOs), Temperature Management, Biologics, Vaccines.